Clinical Trials Logo

Stage IV Uveal Melanoma AJCC v7 clinical trials

View clinical trials related to Stage IV Uveal Melanoma AJCC v7.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03472586 Active, not recruiting - Clinical trials for Metastatic Uveal Melanoma

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Start date: May 2, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.

NCT ID: NCT01587352 Active, not recruiting - Clinical trials for Metastatic Uveal Melanoma

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Start date: April 20, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01585194 Active, not recruiting - Clinical trials for Metastatic Uveal Melanoma

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Start date: November 29, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab and ipilimumab work in treating patients with uveal melanoma that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.